This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Metropolitan Health Networks CEO Discusses Q2 2012 Results - Earnings Call Transcript

Call End 12:10

Metropolitan Health Networks (MDF)

Q2 2012 Earnings Call

August 9, 2012 11:00 AM ET

Executives

Michael Earley - Chairmand & CEO

Roberto Palenzuela - General Counsel & Corporate Secretary

Bob Sabo - CFO

Joe Guethonour - President & COO

Analysts

Matt Weight - Feltl and Company

Josh Raskin - Barclays

Jeff Jonas - Gabelli & Company

Gregory Macosko - Lord Abbett

Alex Clark - Apollo Capital

Matthew Nirenberg - Oppenheimer & Co

Presentation

Operator

Welcome to the second quarter 2012 Metropolitan Health earnings conference call. My name is Monica and I will be your operator for today’s call. (Operator Instructions). I will now turn the call over to Michael Earley, Chairman and CEO. Earley you may begin.

Michael Earley

Thank you Monica. Good morning everyone and welcome to our call. This call is been broadcast over this conference line and is also available via the web as noted in our press release. It will be available in recorded format through the conference service and on our website. Many of you are probably noting our first use of a PowerPoint in today's presentation. We are now finally two-dimensional, we think this is an improvement and will help you better visualize our results and how we look at them. We are being the first time please bear with us, with me this morning are Dr. Joe Guethonour, President and Chief Operating Officer, Bob Sabo, our CFO and Roberto Palenzuela, our General Counsel.

A press release was issued this morning outlining our earnings for the second quarter in a quarterly report on Form 10Q will be filed with the Securities and Exchange Commission shortly. Today I will discuss the continuing growth of our company and related news. Bob will review our financial results for the quarter and first half of the year, Joe will cover some exciting news for us as we move beyond quarter with Humana. And I will close with a few comments, then we will get to Q&A.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs